Skip to main content
Clinical Trials/NCT04717167
NCT04717167
Completed
Not Applicable

The Effect of One Dry Needling Session on Pain and Central Pain Processing in Patients With Knee Osteoarthritis: a Randomized Controlled Trial

Universiteit Antwerpen0 sites61 target enrollmentDecember 1, 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Osteoarthritis, Knee
Sponsor
Universiteit Antwerpen
Enrollment
61
Primary Endpoint
Pain pressure thresholds
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

Research suggests that myofascial trigger points (MTrP) play an important role in explaining pain in patients with musculoskeletal knee disorders. Trigger points are usually defined as hypersensitive tender spots within taut bands of skeletal muscles that are painful on muscle stimulation and that usually elicit referred pain. Treatment of these trigger points could possibly alleviate symptoms in patients with knee pain. However, literature on the effect of trigger point therapy, dry needling in particular, in patients with musculoskeletal knee disorders is scarce. The purpose of this study is to examine the effect of trigger point therapy (dry needling (DN)) on pain, presence of altered central pain processing, muscle features and gait pattern in patients with knee osteoarthritis (KOA). 60 patients with symptomatic KOA will participate in this study. They will randomly be allocated in either an experimental group (EG) (dry needling technique) or a placebo group (PG) (sham needling technique). Pain (Visual analogue scale (VAS) & KOA outcome score (KOOS), muscle features during gait and gait pattern (3D gait analysis and surface electroMyoGraphy (EMG)) and presence of altered central pain processing (Central Sensitization Inventory (CSI), Quantitative Sensory testing (QST)) will be measured at baseline and 15 minutes after the intervention. Additionally, pain will be measured 3 days after the intervention. The investigators hypothesize that the effect on the outcome measures will be significantly larger in the EG compared to the PG.

Registry
clinicaltrials.gov
Start Date
December 1, 2016
End Date
April 1, 2019
Last Updated
5 years ago
Study Type
Interventional
Study Design
Factorial
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Sophie Vervullens

Doctoral Candidate

Universiteit Antwerpen

Eligibility Criteria

Inclusion Criteria

  • A minimum age of fifty years old;
  • Diagnosed with KOA based on the American College of Rheumatology (ACR) clinical classification criteria(48), including:
  • A Kellgren-Lawrence grade of minimum two on radiography;
  • At least three months of chronical knee pain.

Exclusion Criteria

  • Patients suffering from autoimmune and/or neurological disorders
  • Patients who had a major trauma/fracture of the lower limb in the past six months -
  • Patients who experienced other musculoskeletal problems than OA

Outcomes

Primary Outcomes

Pain pressure thresholds

Time Frame: Change from baseline central pain processing at 15minutes postintervention

Measured with an digital algometer (kilogram force/ square cm)

Conditioned pain modulation

Time Frame: Change from baseline central pain processing at 15minutes postintervention

Measured with an digital algometer (test stimulus) and an inflatable cuff (conditioning stimulus). (kilogram force/ square cm)

Pain sensation

Time Frame: Change from 15minutes postintervention pain sensation at 3days postintervention

Measured with the Knee Osteoarthritis Outcome Score- subscale pain, scored on a scale from 0 to 36, transferred from 0 to 100. Higher scores indicate a higher pain sensation.

Temporal summation

Time Frame: Change from baseline central pain processing at 15minutes postintervention

Measured with an digital algometer (kilogram force/ square cm)

Secondary Outcomes

  • Muscle coactivation of musculus Vastus medialis and musculus Biceps femoris(Change from baseline muscle coactivation at 15minutes postintervention)
  • Muscle coactivation of musculus Tibialis anterior and musculus Gastrocnemius medialis(Change from baseline muscle coactivation at 15minutes postintervention)
  • Step time (meters/second)(Change from baseline muscle coactivation at 15minutes postintervention)
  • Muscle coactivation of musculus Vastus medialis and musculus Semitendinosus(Change from baseline muscle coactivation at 15minutes postintervention)
  • Step width (meters)(Change from baseline muscle coactivation at 15minutes postintervention)
  • Muscle coactivation of musculus Vastus lateralis and musculus Semitendinosus(Change from baseline muscle coactivation at 15minutes postintervention)
  • Muscle coactivation of musculus Vastus lateralis and musculus Biceps femoris(Change from baseline muscle coactivation at 15minutes postintervention)
  • Muscle coactivation of musculus Tibialis anterior and musculus Gastrocnemius lateralis(Change from baseline muscle coactivation at 15minutes postintervention)
  • Stride time (seconds)(Change from baseline muscle coactivation at 15minutes postintervention)
  • Stride length (meters)(Change from baseline muscle coactivation at 15minutes postintervention)
  • Step length (meters)(Change from baseline muscle coactivation at 15minutes postintervention)
  • Stance phase (%)(Change from baseline muscle coactivation at 15minutes postintervention)

Similar Trials